arcensus GmbH launches its direct-to-consumer (DTC) service, myLifeHeart, pursuing a revolution in early diagnosis of genetically based heart diseases.
Arndt Rolfs, M.D., co-founder and Medical Director of arcensus. ROSTOCK and BERLIN, Germany – ( Arab Newswire ) -- arcensus GmbH is proud to announce the launch of its direct-to-consumer myLifeHeart™ service, based on Whole Genome Sequencing (WGS) in the Kingdom of Saudi Arabia. It generates actionable genetic and clinical information for all who suffer from hereditary heart conditions, have family members suffer or being diagnosed with a medically relevant heart condition, or seek to prevent genetic heart diseases in future. With myLifeHeart™, arcensus sequences the entire genomic DNA and analyses more than 450 genes related to heart conditions. “myLifeHeart™ makes it possible for everyone to access a diagnosis for heart-diseases from their home, with affordable pricing. The arcensus team has done an outstanding job in developing a service by combining years of scientific research, as well as genetic and medical expertise.” said Arndt ...